ConductScience.org, home

Paper41007774

Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential.

Shatalov PA and 12 others. Biomedicines, 2025. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential. Papers, record 41007774. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007774

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential.
PubMed
Journal
Biomedicines
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
2.31, provisional
iCite
Revised in PubMed
2026-09-25
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shatalov PAPeter Ahttps://orcid.org/0000-0001-5374-8547
2Bukaeva AAAnna Ahttps://orcid.org/0000-0002-5932-1744
3Veselovsky EMEgor Mhttps://orcid.org/0009-0009-3631-6537
4Traspov AAAlexey Ahttps://orcid.org/0000-0003-1618-2577
5Bagdasarova DVDaria Vhttps://orcid.org/0000-0001-9195-4181
6Leukhina IAIrina Ahttps://orcid.org/0000-0002-4073-0679
7Shinkarkina APAnna P
8Raygorodskaya MPMaria P
9Murzaeva AVAlena Vhttps://orcid.org/0009-0002-5770-4669
10Mechenici YAYulia A
11Revkova MAMaria A
12Kaprin ADAndrey D
13Shegai PVPeter V

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References217

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133424836A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens.Front Immunol2020https://conductscience.org/library/papers/33424836PubMed
239213364Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer.Sci Adv2024https://conductscience.org/library/papers/39213364PubMed
316111635Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.Immunity2005https://conductscience.org/library/papers/16111635PubMed
438803496Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies.Front Immunol2024https://conductscience.org/library/papers/38803496PubMed
527081325Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.Clin Med Insights Oncol2016https://conductscience.org/library/papers/27081325PubMed
640281786Comprehensive Analysis of Oncogenic Somatic Alterations of Mismatch Repair Gene in Breast Cancer Patients.Bioengineering (Basel)2025https://conductscience.org/library/papers/40281786PubMed
729567706Personalized vaccines for cancer immunotherapy.Science2018https://conductscience.org/library/papers/29567706PubMed
838417916CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.J Immunother Cancer2024https://conductscience.org/library/papers/38417916PubMed
919002680NetMHCpan, a method for MHC class I binding prediction beyond humans.Immunogenetics2009https://conductscience.org/library/papers/19002680PubMed
1038503296FDA approval of the first cellular therapy for a solid (non-hematologic) cancer.Mol Ther2024https://conductscience.org/library/papers/38503296PubMed
1135387130A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.Front Oncol2022https://conductscience.org/library/papers/35387130PubMed
1239929822Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer.NPJ Breast Cancer2025https://conductscience.org/library/papers/39929822PubMed
1329755464Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer.Front Immunol2018https://conductscience.org/library/papers/29755464PubMed
1436318382EGFR as a potent CAR T target in triple negative breast cancer brain metastases.Breast Cancer Res Treat2023https://conductscience.org/library/papers/36318382PubMed
1539023168Engineered CAR-NK Cells with Tolerance to H2O2 and Hypoxia Can Suppress Postoperative Relapse of Triple-Negative Breast Cancers.Cancer Immunol Res2024https://conductscience.org/library/papers/39023168PubMed
1622186794The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.Mol Ther2012https://conductscience.org/library/papers/22186794PubMed
1731611695Predicting HLA class II antigen presentation through integrated deep learning.Nat Biotechnol2019https://conductscience.org/library/papers/31611695PubMed
1836434591Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.BMC Cancer2022https://conductscience.org/library/papers/36434591PubMed
1940033418Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer.Exp Hematol Oncol2025https://conductscience.org/library/papers/40033418PubMed
2040574862Advances and challenges in neoantigen prediction for cancer immunotherapy.Front Immunol2025https://conductscience.org/library/papers/40574862PubMed

See all 217 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42846762Advancements in polymer-based drug delivery systems targeting the tumor microenvironment for immunotherapy of triple-negative breast cancer.Front Immunol2026https://conductscience.org/library/papers/42846762PubMed
42539001Genetic and Pharmacologic Targeting of Eya3 in Macrophages Drives Anti-Tumor Immunity in Triple-Negative Breast Cancer.bioRxiv2026https://conductscience.org/library/papers/42539001PubMed
42353619Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42353619PubMed
42147479Triple-negative breast cancer: current understanding and future perspectives.Explor Target Antitumor Ther2026https://conductscience.org/library/papers/42147479PubMed
42120393Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions.NPJ Breast Cancer2026https://conductscience.org/library/papers/42120393PubMed
42099744Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers.Oncol Rev2026https://conductscience.org/library/papers/42099744PubMed
42035063Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.Mol Cancer2026https://conductscience.org/library/papers/42035063PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
TP537157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41007774

GET https://conductscience.org/api/papers/v1/41007774/references?page=2